Immunotherapy, cancer treatments that alter the immune system, making it better apt to fight tumor cells, have provided novel ...

Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ ...

"Howard Stern Show" sidekick Robin Quivers, 72, has inspired women across the nation with her resilience through her ...

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") highlights the potential for ...

Dual blocking SHP2 and FGFR2 can not only promote the targeted tumor-killing effects and overcome FGFR2 inhibitor resistance caused by feedback activation, but also activate T cell-mediated anti-tumor ...

ImmunityBio, Inc. , a leading immunotherapy company, today announced significant progress in its ongoing discussions with the U.S. Food and Drug Administration (FDA) regarding three areas of its ...

Cancer is a multifactorial disease that affects millions of individuals worldwide and has a profound impact on public health. The heterogeneity of solid ...

Two independent studies reveal that disease progression is delayed by combining two targeted therapies with the traditional ...

The virus often mutates by simply deleting small pieces of its genetic code. The mutations "disguise" the virus from antibodies. Zachary Levi calls for California leadership to be 'held ...

We work right across the cancer research pathway with strengths ranging from cell biology to healthcare research. We aim to nurture the thought leaders of today and tomorrow through the provision of ...

This strategy not only intensifies immune responses but also improves the durability of treatment by overcoming tumor immune escape mechanisms. Despite the immense potential of VLPs in cancer ...

and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells. By activating NK cells, ANKTIVA overcomes the tumor escape phase of clones resistant to T cells ...